Scarica l'app Stockscreener
34.08
0.29%
-0.10
Dopo l'orario di chiusura:
34.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$34.18
Aprire:
$33.5
Volume 24 ore:
2.26M
Relative Volume:
0.99
Capitalizzazione di mercato:
$5.91B
Reddito:
-
Utile/perdita netta:
$-354.30M
Rapporto P/E:
-13.51
EPS:
-2.5234
Flusso di cassa netto:
$-286.27M
1 W Prestazione:
-2.49%
1M Prestazione:
-17.94%
6M Prestazione:
-7.09%
1 anno Prestazione:
+167.29%
Intervallo 1D:
$33.07
$34.19
Intervallo di 1 settimana:
$33.07
$35.75
Portata 52W:
$11.60
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
34.08 | 5.93B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Cogent Biosciences Stock Price Forecast. Should You Buy COGT? - StockInvest.us
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia - marketscreener.com
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Australia
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences director Arlene Morris sells $1.69m shares - Investing.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Barchart.com
Cogent Biosciences (COGT) Slides 6.5% to $34.67 as Support and Resistance Levels Come into FocusETF Premium Discount - dars.gov.et
Cogent Biosciences Inc. (COGT) Peer Comparison – Compare with Others - Value Research
Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead - Stock Titan
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results: Shares Fall 0.91% in the Latest SessionAnalyst Earnings Estimate - vinanet.vn
Cogent (COGT) Earnings Reading: The Available Earnings Metric Delivers a Miss on the Day; Price Move - vinanet.vn
What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders - simplywall.st
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (COGT) Edges Higher to $38.98, Holding Ground Between Key Technical LevelsSmart Beta Flow - vinanet.vn
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesLate Stage Breakouts - vinanet.vn
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences set to report earnings ahead of FDA decisions By Investing.com - Investing.com Canada
Cogent Biosciences set to report earnings ahead of FDA decisions - Investing.com
Is Cogent Biosciences Inc (COGT) Worth the Risk After Q2 Earnings Miss? GF Score: 25/100 - GuruFocus
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss - marketscreener.com
Form 8K Cogent Biosciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Cogent Biosciences Q2 EPS of $(0.52) beats estimates by 8.77% - scanx.trade
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results - MarketBeat
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, Vs. FactSet Est of $98M Loss - Moomoo
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach - Quiver Quantitative
Cogent Biosciences Q2 net loss widens on higher expenses - TradingView
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib - Stock Titan
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. - Stock Titan
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):